--- title: "Pre-market trend | CONSUN PHARMA (1681.HK) 5/6 moderately increased with volume, is capital flowing back into the pharmaceutical sector?" type: "News" locale: "en" url: "https://longbridge.com/en/news/285339284.md" description: "CONSUN PHARMA has recently shown a steady upward trend, with an increase of approximately 12.27%. The MACD daily bullish signal is gradually being established, with the fast and slow lines crossing above the zero axis, which usually indicates that the medium-term trend is transitioning from a consolidation phase to an upward breakout. The trading volume is about HKD 72.39 million, which, although not a large absolute amount, has significantly increased compared to the stock's historical average daily volume, indicating a rise in capital participation. The stock price is steadily rising, and the short-term moving averages are beginning to turn upward, forming an initial bullish arrangement. On the news front, the overall recovery trend in the pharmaceutical sector is evident. The Hong Kong stock biopharmaceutical index has stabilized and rebounded, with AKESO rising over 4% on the day and BEONE MEDICINES increasing nearly 3%, showing clear signs of capital returning to the sector. As a leader in the traditional Chinese medicine nephrology field, CONSUN PHARMA has a stable product matrix and excellent cash flow performance, making it a defensive yet flexible choice in the rotation of the pharmaceutical sector. Additionally, the domestic medical insurance policy's supportive stance towards traditional Chinese medicine remains unchanged, and the impact of centralized procurement on exclusive varieties is limited. The company's fundamentals are relatively certain, attracting some funds seeking stable returns. From a technical perspective, the current stock price is operating above the 5-day and 10-day moving averages, with both moving averages trending upward and maintaining a moderate distance, forming a step-like support. If today's trading volume remains above HKD 70 million and holds above the 5-day moving average, the upward trend is expected to continue. Attention should be paid to the previous high-pressure zone above, as a breakthrough may open up new upward space. The correlation between the Hong Kong pharmaceutical sector and the A-share market is worth noting, as the A-share market has also been active in the innovative drug sector recently" datetime: "2026-05-07T01:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285339284.md) - [en](https://longbridge.com/en/news/285339284.md) - [zh-HK](https://longbridge.com/zh-HK/news/285339284.md) --- # Pre-market trend | CONSUN PHARMA (1681.HK) 5/6 moderately increased with volume, is capital flowing back into the pharmaceutical sector? CONSUN PHARMA has recently shown a steady upward trend, with an increase of approximately 12.27%. The MACD daily bullish signal is gradually being established, with the fast and slow lines crossing above the zero axis, which usually indicates that the medium-term trend is transitioning from a sideways movement to an upward breakout. The trading volume is about HKD 72.39 million, which, although not a large absolute amount, shows a significant increase compared to the stock's historical average daily volume, indicating an increase in capital participation. The stock price is steadily rising, and the short-term moving averages are beginning to turn upward, forming an initial bullish arrangement. On the news front, the pharmaceutical sector has shown a clear overall warming trend recently. The Hong Kong biotechnology index has stabilized and rebounded, with AKESO rising over 4% on the day and BEONE MEDICINES increasing nearly 3%, indicating clear signs of capital returning to the sector. As a leader in the traditional Chinese medicine nephrology field, CONSUN PHARMA has a stable product matrix and excellent cash flow performance, making it a defensive yet flexible option in the rotation of the pharmaceutical sector. Additionally, the domestic medical insurance policy's supportive stance towards traditional Chinese medicine remains unchanged, and the impact of centralized procurement on exclusive varieties is limited. The company's fundamentals are relatively certain, attracting some funds seeking stable returns. From a technical perspective, the current stock price is operating above the 5-day and 10-day moving averages, with both averages trending upward and maintaining a moderate distance, forming a step-like support. If today's trading volume remains above HKD 70 million and holds above the 5-day moving average, the upward trend is expected to continue. Attention should be paid to the previous high-pressure zone above, as a breakout may open up new upward space. The correlation between the Hong Kong pharmaceutical sector and the A-share market is worth noting, as the A-share market's innovative drug sector has also been active recently. The short-term trend is biased towards bullishness, with healthy volume-price coordination and a warming sector atmosphere providing support. The risk lies in the relatively limited liquidity of small and mid-cap pharmaceutical stocks; if sector sentiment cools or market style shifts towards large-cap stocks, stock price volatility may increase. _This article provides only technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances._ ### Related Stocks - [01681.HK](https://longbridge.com/en/quote/01681.HK.md) - [09926.HK](https://longbridge.com/en/quote/09926.HK.md) - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) ## Related News & Research - [BeOne Medicines Ltd (6160) Gets a Buy from CMBC International](https://longbridge.com/en/news/285886964.md) - [NYC Health and Hospitals says hackers stole medical data and fingerprints during breach affecting at least 1.8 million people](https://longbridge.com/en/news/286799449.md) - [ZTO Express details board roles and committee structure](https://longbridge.com/en/news/286981772.md) - [09:15 ETNewport Healthcare's 2025 Outcomes Report Demonstrates Significant Improvements in Teen and Young Adult Mental Health Following Treatment](https://longbridge.com/en/news/286920260.md) - [12:36 ETDiagnostics Direct LLC Wins Innovation Award from Johns Hopkins](https://longbridge.com/en/news/286945918.md)